GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » Short Interest

Satellos Bioscience (TSX:MSCL) Short Interest


View and export this data going back to 2021. Start your Free Trial

What is Satellos Bioscience Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Satellos Bioscience's Short Interest

For the Biotechnology subindustry, Satellos Bioscience's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Satellos Bioscience's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Satellos Bioscience's Short Interest distribution charts can be found below:

* The bar in red indicates where Satellos Bioscience's Short Interest falls into.


Satellos Bioscience (TSX:MSCL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » Short Interest
Comparable Companies
TSX:MBX TSXV:GSD TSX:ATE XCNQ:GLAB TSX:TH TSX:HBP TSXV:TTI XCNQ:ACOG TSXV:DMT TSXV:COV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
MSCLF:USA 0IT:Germany
Address
65 Front Street East, Suite 201, Toronto, ON, CAN, M5E 1B5
Website
https://www.satellos.com
Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Satellos Bioscience (TSX:MSCL) Headlines

No Headlines